Michael E. Engel, MD, PhD, FAAP

Research Interests

  • Childhood Acute Leukemia
  • Hematopoiesis

Labs

Lab Website

Languages

  • English

Academic Information

  • Departments: Oncological Sciences - Adjunct Associate Professor, Pediatrics - Adjunct Associate Professor
  • Divisions: Pediatric Hematology/Oncology
  • Cancer Center Programs: Nuclear Control of Cell Growth & Differentiation

Board Certification

  • American Board of Pediatrics (Pediatrics)
  • American Board of Pediatrics (Sub: Pediatric Hematology-Oncology)

Academic Office Information

  • 801-587-3882
  • Huntsman Cancer Institute
    2000 Circle of Hope, Room: 4243
    Salt Lake City, UT 84112

Academic Bio

Michael Engel, MD, PhD, attended the Vanderbilt University School of Medicine in Nashville, TN. He completed his Pediatric residency training and subspecialty training in Pediatric Hematology/Oncology at the Monroe Carell Jr. Children's Hospital at Vanderbilt. He recently joined the faculty of the University of Utah School of Medicine and Primary Children's Medical Center as Assistant Professor in the Division of Pediatric Hematology/Oncology and as Adjunct Assistant Professor in the Department of Oncological Sciences of the Huntsman Cancer Institute.

Dr. Engel's clinical interests encompass hematologic and oncologic illness in children, adolescents and young adults, with an emphasis on hematologic malignancies including myeloid and lymphoid leukemias.

Dr. Engel's laboratory research interests involve the molecular machinery governing normal hematopoiesis and the molecular pathogenesis of acute leukemias, with a focus on alterations to the signaling machinery that govern cell growth and development. In the clinical domain, Dr. Engel is an active participant in clinical and translational research as a member of the Children's Oncology Group and as a leader within the Center for Children's Cancer Research of the Huntsman Cancer Institute.

As a member of the teaching faculty, Dr. Engel has a long-standing commitment to teaching and mentoring in both the clinical and laboratory domains. His teaching roles have involved learners at the pre- and post-doctoral levels and encompass both didactic and small group settings. He serves as Director of the Pediatric Hematology/Oncology Fellowship Program at the University of Utah and Primary Children's Medical Center.

Dr. Engel is a past recipient of a National Young Investigator award from the American Society of Pediatric Hematology/Oncology, a Ruth Kirschstein fellowship from the National Cancer Institute, a young investigator award from Alex's Lemonade Stand Pediatric Cancer Research Foundation, and served as a Hyundai Hope on Wheels Foundation Scholar. His research is currently supported by a Research Scholar Award from the St. Baldrick's Pediatric Cancer Research Foundation, research grants from CureSearch and Hope Street Kids foundations and a K08 Career Development Award from the National Institutes of Health. In the clinical setting, Dr. Engel is the recipient of a prestigious PRC Top Performer Award for 100th percentile patient satisfaction.

Education History

Type School Degree
Research Fellow Vanderbilt University Medical Center
Department of Biochemistry
Research Fellow
Fellowship Vanderbilt University Medical Center
Pediatric Hematology/Oncology
Clinical Fellow
Residency Vanderbilt University Medical Center
Pediatrics – Special Alternative Pathway Trainee
Resident
Professional Medical Vanderbilt University School of Medicine
Medical Scientist Training Program
M.D.
Doctoral Training Vanderbilt University School of Medicine
Medical Scientist Training Program
Ph.D.
Other Training Vanderbilt University School of Medicine
Medical Scientist Training Program
Undergraduate Purdue University, West Lafayette Campus
Biology
B.S.

Selected Publications

Journal Article

  1. Mixon BA, Eckrich MJ, Lowas S, Engel ME (2013). Vincristine, irinotecan, and temozolomide for treatment of relapsed alveolar rhabdomyosarcoma. J Pediatr Hematol Oncol, 35(4), e163-6.
  2. Fagan E, Slone J, Shoemaker A, Black J, Berlin J, Engel ME (April 2012). Neuroendocrine carcinoma in an adolescent with hypercortisolemia. J Pediatr Hematol Oncol, 34(3), 117-119.
  3. Barrett CW, Smith JJ, Lu LC, Markham N, Stengel KR, Short SP, Zhang B, Hunt AA, Fingleton BM, Carnahan RH, Engel ME, Chen X, Beauchamp RD, Wilson KT, Hiebert SW, Reynolds AB, Williams CS (2012). Kaiso directs the transcriptional corepressor MTG16 to the Kaiso binding site in target promoters. PLoS ONE, 7(12), e51205.
  4. Engel ME, Nguyen HN, Mariotti J, Hunt A, Hiebert SW (2010). Myeloid translocation gene 16 (MTG16) interacts with Notch transcription complex components to integrate Notch signaling in hematopoietic cell fate specification. Mol Cell Biol, 30(7), 1852-63.
  5. Chyla BJ, Moreno-Miralles I, Steapleton MA, Thompson MA, Bhaskara S, Engel M, Hiebert SW (2008). Deletion of Mtg16, a target of t(16;21), alters hematopoietic progenitor cell proliferation and lineage allocation. Mol Cell Biol, 28(20), 6234-47.
  6. Frangoul H, Wills M, Crossno C, Engel M, Domm J (2007). Acyclovir-resistant herpes simplex virus pneumonia post-unrelated stem cell transplantation: a word of caution. Pediatr Transplant, 11(8), 942-4.
  7. Engel ME, Hickstein DD, Bauer TR Jr, Calder C, Manes B, Frangoul H (2006). Matched unrelated bone marrow transplantation with reduced-intensity conditioning for leukocyte adhesion deficiency. Bone Marrow Transplant, 37(7), 717-8.
  8. Bhowmick NA, Ghiassi M, Bakin A, Aakre M, Lundquist CA, Engel ME, Arteaga CL, Moses HL (2001). Transforming growth factor-beta1 mediates epithelial to mesenchymal transdifferentiation through a RhoA-dependent mechanism. Mol Biol Cell, 12(1), 27-36.
  9. Engel ME, McDonnell MA, Law BK, Moses HL (1999). Interdependent SMAD and JNK signaling in transforming growth factor-beta-mediated transcription. J Biol Chem, 274(52), 37413-20.
  10. Sarkar DK, Pastorcic M, De A, Engel M, Moses H, Ghasemzadeh MB (1998). Role of transforming growth factor (TGF)-beta Type I and TGF-beta type II receptors in the TGF-beta1-regulated gene expression in pituitary prolactin-secreting lactotropes. Endocrinology, 139(8), 3620-8.
  11. Engel ME, Datta PK, Moses HL (1998). RhoB is stabilized by transforming growth factor beta and antagonizes transcriptional activation. J Biol Chem, 273(16), 9921-6.
  12. Kawabata M, Imamura T, Miyazono K, Engel ME, Moses HL (1995). Interaction of the transforming growth factor-beta type I receptor with farnesyl-protein transferase-alpha. J Biol Chem, 270(50), 29628-31.
  13. Vedvick T, Buckholz RG, Engel M, Urcan M, Kinney J, Provow S, Siegel RS, Thill GP (1991). High-level secretion of biologically active aprotinin from the yeast Pichia pastoris. J Ind Microbiol, 7(3), 197-201.

Review

  1. Engel ME, Datta PK, Moses HL (1998). Signal transduction by transforming growth factor-beta: a cooperative paradigm with extensive negative regulation. [Review]. J Cell Biochem Suppl, 30-31, 111-22.

Book Chapter

  1. Engel ME, and Hiebert SW (2010). Proleukemic RUNX1 and CBFbeta mutations in the pathogenesis of acute leukemia. In Lalitha Nagarajan, PhD (Eds.), Cancer Treatment and Research (Acute Myelogenous Leukemia-Genetics, Biology and Therapy, 145, pp. 127-147). New York: Springer.

Abstract

  1. Singer J, Andrade D, Bareyan D, McClellan D, Lucente H, Velinder M, Chandrasekharan M, Theisen E, Liu F, Sharma S, Maese L and Engel ME (2013). Notch alters sumoylation to govern GFI1 protein stability and support its transcriptional repression function [Abstract]. American Society of Hematology National Meeting, New Orleans, LA.
  2. Singer J, Andrade D, Bareyan D, McClellan D, Lucente H, Velinder M, Chandrasekharan M, Theisen E, Liu F, Sharma S and Engel ME (2013). Lysine Specific Demethylase-1 inhibition as a therapeutic strategy that leverages the requirement for Growth Factor Indepndence-1 in Notch-driven T-ALL [Abstract]. American Association for Cancer Research-Pediatric Oncology Working Group--Pediatric Cancer at the Crossroads-Translating discovery into improved outcomes.
  3. Andrade D, Maese L, Singer J, Bareyan D, McClellan D, Lucente H, Quinton R, Chandrasekharan M, Liu F, and Engel ME (2013). Sumoylation regulates the half-life of Growth Factor Independence (GFI)-1 to modulate transcriptional repression [Abstract]. ASPHO National Meeting, Miami, FL.
  4. Andrade D, Singe J, Bareyan D, McClellan D, Lucente H, Chandrasekharan M, and Engel ME (2013). Notch and PIAS3 differentially regulate sumoylation of GFI1 to modulate transcriptional repression [Abstract]. AACR National Meeting, Washington, DC.
  5. Andrade DL, Bareyan D, Singer J, Quinton R, Engel ME (2012). Regulation of GFI1 proteins by Notch intracellular domains [Abstract]. American Association for Cancer Research National Meeting.
  6. Mangrum DS, Shams S, Downie J, von Schwelder U, Rodic V, Engel ME, Barnette P, Frazer JK, Trede N, Pei D, Cheng C, Mullighan C, Yang J, Miles R, Schiffman JD (2011). Focal 22q11.22 loss combined with IKZF1 alterations predict very poor outcome in childhood acute lymphoblastic leukemia [Abstract]. American Society of Hematology National Meeting, San Diego, CA.
  7. Mariotti J, Nguyen HN and Engel ME (2010). Structure—function relationships between RUNX1-MTG fusion proteins and core components of the Notch transcription complex [Abstract]. American Association for Cancer Research National Meeting. Washington, DC.

Other

  1. Engel ME, Hiebert SW (2010). The enemy within: dormant retroviruses awaken. Utah Special Educator (16(5), pp. 517-8). United States.
  2. Engel ME (1999). Rho GTP-Binding Proteins and the C-Jun N-Terminal Kinase Cascade. Ph.D. Thesis. Vanderbilt University.

Patent

  1. Engel ME, Vedvick T, Urcan M, Buckholz R, and Kinney J (1993). Expression System for Bovine Pancreatic Trypsin Inhibitor (BPTI/Aprotinin) Peptides. U.S. Patent No. US5258302. Washington, D.C.:U.S. Patent and Trademark Office.

U of U Health News

    Video